We are live on ! Find out more
DYN icon

Dyne Therapeutics

207 hedge funds and large institutions have $1.97B invested in Dyne Therapeutics in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 111 increasing their positions, 38 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 38

61% more capital invested

Capital invested by funds: $1.23B → $1.97B (+$747M)

44% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 27

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

5% more funds holding

Funds holding: 197207 (+10)

3.61% less ownership

Funds ownership: 113.15%109.54% (-3.6%)

24% less call options, than puts

Call options by funds: $2.45M | Put options by funds: $3.22M

Holders
207
Holders Change
+10
Holders Change %
+5.08%
% of All Funds
2.72%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.09%
New
39
Increased
111
Reduced
38
Closed
27
Calls
$2.45M
Puts
$3.22M
Net Calls
-$766K
Net Calls Change
-$333K
Name Holding Trade Value Shares
Change
Change in
Stake
DTC
26
Deep Track Capital
Connecticut
$25.3M +$22.8M +2,000,000 New
Goldman Sachs
27
Goldman Sachs
New York
$24M +$6.38M +559,772 +42%
PBA
28
Paradigm Biocapital Advisors
New York
$24M +$21.7M +1,898,950 New
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$21.7M +$18.2M +1,594,523 +1,293%
MB
30
MPM BioImpact
Massachusetts
$18.3M
Morgan Stanley
31
Morgan Stanley
New York
$18M +$648K +56,831 +4%
Franklin Resources
32
Franklin Resources
California
$17.7M +$95.7K +8,390 +0.6%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$17.7M -$11.2M -985,866 -41%
PAI
34
Palo Alto Investors
California
$16M +$11.4M +997,698 +377%
Northern Trust
35
Northern Trust
Illinois
$13.1M +$2.24M +196,531 +23%
Charles Schwab
36
Charles Schwab
California
$12.7M +$2.99M +262,123 +35%
SI
37
Sofinnova Investments
California
$12.5M +$4.23M +370,963 +60%
FCM
38
Frontier Capital Management
Massachusetts
$11.5M +$1.39M +121,494 +15%
CS
39
Candriam SCA
Luxembourg
$10.5M +$3.53M +309,761 +59%
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$10.5M +$431K +37,782 +5%
RSCM
41
Rock Springs Capital Management
Maryland
$10.4M +$2.77M +243,063 +42%
IHAM
42
Integral Health Asset Management
New York
$10.1M +$9.12M +800,000 New
ACH
43
ArrowMark Colorado Holdings
Colorado
$9.94M +$179K +15,690 +2%
Bank of America
44
Bank of America
North Carolina
$9.63M +$2.82M +247,311 +48%
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$9.23M +$8.32M +729,606 New
Voloridge Investment Management
46
Voloridge Investment Management
Florida
$8.98M -$925K -81,076 -10%
NCM
47
Nantahala Capital Management
Connecticut
$8.89M -$481K -42,178 -6%
MAM
48
MPM Asset Management
Massachusetts
$8.63M
JG
49
Jain Global
New York
$8.15M +$546K +47,915 +8%
Aberdeen Group
50
Aberdeen Group
United Kingdom
$7.04M +$830K +72,770 +15%

DYN Hedge Fund Activity: Q3 2025 in Review

207 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2025, worth a combined $1.97B — up 61% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new DYN positions and 27 closed out — a net gain of 12 holders — while 111 added to existing stakes and 38 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $60.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $92.5M sold.

  • 207 institutional investors held Dyne Therapeutics (DYN) as of Q3 2025, up from 197 in Q2 2025.
  • Funds reported $1.97B of Dyne Therapeutics stock for Q3 2025, up 61% quarter-over-quarter.
  • 39 funds opened new Dyne Therapeutics positions in Q3 2025 and 27 closed out, a net change of +12 holders.
  • The largest Dyne Therapeutics buyer in Q3 2025 was Janus Henderson Group, an estimated $60.5M added.
  • The largest Dyne Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $92.5M sold.

Based on aggregated 13F filings for Q3 2025.